Synlogic, Inc. (NASDAQ:SYBX) Short Interest Update

Synlogic, Inc. (NASDAQ:SYBX) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totalling 61,000 shares, a drop of 30.9% from the December 15th total of 88,300 shares. Based on an average daily trading volume, of 33,100 shares, the days-to-cover ratio is presently 1.8 days. Currently, 0.9% of the shares of the company are sold short.

Synlogic Stock Up 1.4 %

Shares of SYBX opened at $1.44 on Wednesday. The stock’s 50-day moving average price is $1.42 and its 200 day moving average price is $1.47. Synlogic has a 12-month low of $1.22 and a 12-month high of $3.86. The firm has a market capitalization of $16.84 million, a price-to-earnings ratio of -0.35 and a beta of 0.80.

Synlogic (NASDAQ:SYBX) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.17. Synlogic had a negative net margin of 2,284.65% and a negative return on equity of 207.84%. Equities research analysts expect that Synlogic will post -2.71 EPS for the current year.

About Synlogic

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.